Factors."Our CompanyWe are a biotechnology company using proprietary taste receptor-based assays and screening technologies to discover and develop novel flavors and flavor enhancers
the second half of 2005 our collaborator will begin to test market products containing our savory flavors and flavor enhancers for commercialization.•Sweet Program:We have identified and developed S395 and S888, lead compounds that enhance the sweet taste of
enhancers to enable our collaborators to significantly reduce the levels of sugar, salt and MSG in packaged food and beverage products while maintaining or improving taste.•Obtaining Exclusive Use of Proprietary Flavors and Flavor Enhancers.We are able to offer our collaborators
the closing of this offering.Years ended December 31,Three months ended March 31,1999200020012002200320032004(Unaudited)(Unaudited)(In thousands, except share and per share data)Statements of Operations Data:Revenue under collaborative agreements$—$115$2,275$7,327$9,537$2,203$2,241Operating expenses:Research and development1556,13716,26317,63516,8024,0023,950General and administrative1,1723,1964,9524,1544,0961,2751,010Stock-based compensation:Research and development841,8541,2405401,293248593General and administrative123723781584,997301,687Total operating expenses1,42311,55922,83322,48727,1885,5557,240Loss from operations(1,423)(11,444)(20,558)(15,160)(17,651)(3,352)(4,999)Interest income (expense), net(10)6993293391985640Net loss$(1,433)$(10,745)$(20,229)$(14,821)$(17,453)$(3,296)$(4,959)Basic and diluted net loss per share(1):Historical$(3.00)$(12.30)$(17.30)$(9.60)$(10.03)$(1.97)$(2.63)Pro Forma$(0.97)$(0.27)Shares used to compute basic and diluted net loss per share(1):Historical477,368873,2411,169,1341,544,2681,739,3801,672,3111,887,674Pro Forma17,944,68618,092,980(1)Please
and any other possible future collaborators to commercialize any flavors or flavor enhancers that we successfully develop and to provide the sales, marketing and distribution capabilities required for
Each of our current collaboration agreements provides that we will conduct research and development on flavors and flavor enhancers for use within one or more defined
We may not be able to develop flavors or flavor enhancers that meet these criteria.If we or our collaborators are unable to obtain and maintain the GRAS determination or regulatory approval required before any flavors or flavor enhancers can be incorporated into products that are
and industry specific economic conditions, which may affect our collaborators' research and development expenditures.We may need to obtain additional capital to fund our operations.If we are unable to successfully commercialize our flavors and flavor enhancers, we may need to obtain additional capital or change our strategy to continue our
limitations on additional borrowing, specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.If we lose our key personnel or are unable to attract and retain qualified personnel, it could adversely affect our business.Our success depends to a significant degree upon the continued contributions of our executive officers, management and scientific staff.
products developed as a result of our competitors' existing or future collaborations will not compete with our flavors and flavor enhancers.Universities
Our failure to compete effectively would have a significant adverse effect on our business, financial condition and results of operations.We may be sued for product liability, which could adversely affect our business.Because our business strategy involves the development and sale by our collaborators of commercial products incorporating our flavors and flavor enhancers, we may
the date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock.23USE OF PROCEEDSWe estimate that the net proceeds from this offering without the exercise of the underwriters' over-allotment option will be approximately $34.9 million, based
technologies, product rights or businesses, although we have no current agreements or commitments for, nor are we actively seeking, any such acquisition.We estimate we will use approximately $6 million to $10 million of the net proceeds of this offering, assuming no exercise of the underwriters' over-allotment option, to
the notes to such statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations."Years ended December 31,Three Months Ended March 31,1999200020012002200320032004(Unaudited)(Unaudited)(In thousands, except share and per share data)Statements of Operations Data:Revenue under collaborative agreements$—$115$2,275$7,327$9,537$2,203$2,241Operating expenses:Research and development1556,13716,26317,63516,8024,0023,950General and administrative1,1723,1964,9524,1544,0961,2751,010Stock-based compensation:Research and development841,8541,2405401,293248593General and administrative123723781584,997301,687Total operating expenses1,42311,55922,83322,48727,1885,5557,240Loss from operations(1,423)(11,444)(20,558)(15,160)(17,651)(3,352)(4,999)Interest income (expense), net(10)6993293391985640Net loss$(1,433)$(10,745)$(20,229)$(14,821)$(17,453)$(3,296)$(4,959)Basic and diluted net loss per share(1):Historical$(3.00)$(12.30)$(17.30)$(9.60)$(10.03)$(1.97)$(2.63)Pro Forma$(0.97)$(0.27)Shares used to compute basic and diluted net loss per share(1):Historical477,368873,2411,169,1341,544,2681,739,3801,672,3111,887,674Pro Forma17,944,68618,092,980(1)Please
this prospectus.OverviewWe are a biotechnology company using proprietary taste receptor-based assays and screening technologies to discover and develop novel flavors and flavor enhancers
addition, in the event our collaborators launch products incorporating our flavors and flavor enhancers, we will receive royalty payments based upon the future sales of those
months ended March 31, 2003 to 2004 was primarily the result of the net effect of the following costs:Salaries and Personnel.Our expenses for research and development personnel, including consultants,
reduce overall raw material ingredient costs, particularly for those products containing high levels of natural and artificial sweeteners and MSG.Our StrategyOur goal is to become the leader in discovering, developing and commercializing new and improved flavors and flavor enhancers.
reduce overall raw material ingredient costs, particularly for those products containing high levels of natural and artificial sweeteners and MSG.Our StrategyOur goal is to become the leader in discovering, developing and commercializing new and improved flavors and flavor enhancers.
intend to receive from future collaborators license fees, research and development funding, milestone payments and royalties on future sales of products incorporating these flavors and flavor
of our collaboration agreements provides that we will conduct research and development on flavors and flavor enhancers for use within clearly defined packaged food and beverage